USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility

Cipla Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500087 | NSE: CIPLA

31 May 2025 Evaluate

United States Food and Drugs Administration (USFDA) has concluded current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility in Bommasandra, Bengaluru. The inspection conducted from May 26, 2025 to May 30, 2025.

On conclusion of the inspection, the company received one observation in Form 483. The company will work closely with the USFDA and remains committed to address the observation comprehensively within stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.50
Dr. Reddys Labs.	1202.80
Cipla	1397.20
Lupin	2090.00
Zydus Lifesciences	1202.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.